|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C11H13N.HCl |
|||
| Molecular Weight | 195.69 | CAS No. | 306-07-0 | |
| Solubility (25°C)* | In vitro | DMSO | 39 mg/mL (199.29 mM) | |
| Water | 39 mg/mL (199.29 mM) | |||
| Ethanol | 39 mg/mL (199.29 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Pargyline is an irreversible inhibitor of monoamine oxidase (MAO)-B with Ki values of 13 and 0.5 μM for time-dependent inhibition of the activity of MAO-A and -B, respectivey. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro | Pargyline, an MAO inhibitor, prevents the activity of lysine-specific demethylase 1 (LSD1) and is excessively expressed in breast cancer. The proliferation of cells exposed to pargyline decreases in a dose- and time-dependent manner. The treatment of 2 mM pargyline exhibits an increase of the cell proportion at the G1 phase, while the major decrease of the cell proportion is at the S phase. pargyline induces an increase in the cleaved PARP expression[2]. | ||||
| In vivo | Chronic treatment (14 days) with pargyline (10 mg/kg) markedly down-regulate the density of NAIBS (non-adrenoceptor idazoxan binding sites) in the rat brain[3]. |
Protocol (from reference)
| Cell Assay:[2] |
|
|---|---|
| Animal Study:[3] |
|
References
Selleck's Pargyline hydrochloride has been cited by 2 publications
| Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models [ Genome Med, 2021, 13(1):168] | PubMed: 34702310 |
| Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. [ Cancer Lett, 2017, 398:12-21] | PubMed: 28377178 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.